Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 1/20 | 0.44 |
| ▸ | CXCR3 | P49682 | 8/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | GNRHR | P30968 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 3/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | EDNRB | P24530 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5137557 | 0.88 | C5AR1 (0.42) | C5AR1BCHEKCNH2 | |
| SCHEMBL5135945 | 0.86 | C5AR1 (0.57) | C5AR1 | |
| SCHEMBL648140 | 0.84 | C5AR1 (0.44) | C5AR1CXCR3 | |
| SCHEMBL5137356 | 0.84 | MEN1 (0.45) | C5AR1CNR2 | |
| SCHEMBL648304 | 0.84 | C5AR1 (0.41) | C5AR1BCHE | |
| SCHEMBL5136874 | 0.84 | C5AR1 (0.54) | C5AR1CXCR3KCNH2 | |
| SCHEMBL648105 | 0.84 | C5AR1 (0.38) | C5AR1CNR2BCHE | |
| SCHEMBL4766337 | 0.84 | C5AR1 (0.38) | C5AR1CNR2BCHE | |
| SCHEMBL649149 | 0.83 | C5AR1 (0.64) | C5AR1 | |
| SCHEMBL5134570 | 0.83 | C5AR1 (0.54) | C5AR1CXCR3BCHEKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1322309-B1 | HIGH AFFINITY SMALL MOLECULE C5A RECEPTOR MODULATORS | NEUROGEN CORP (US) | 2008-08-13 | — | — | EP | claimed |
| EP-1322309-A4 | HIGH AFFINITY SMALL MOLECULE C5A RECEPTOR MODULATORS | NEUROGEN CORP (US) | 2004-10-13 | — | — | EP | claimed |
| EP-1322309-A2 | HIGH AFFINITY SMALL MOLECULE C5A RECEPTOR MODULATORS | Neurogen Corporation (US) | 2003-07-02 | — | — | EP | claimed |
| WO-2002049993-A2 | HIGH AFFINITY SMALL MOLECULE C5A RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2002-06-27 | — | — | WO | claimed |
| US-7271270-B2 | High affinity small molecule C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-09-18 | — | — | US | disclosed |
| US-7271270-B2 | High affinity small molecule C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-09-18 | — | — | US | disclosed |
| US-20070027158-A1 | High affinity small molecule C5a receptor modulators | NEUROGEN CORPORATION | 2007-02-01 | — | — | US | disclosed |
| US-20070027158-A1 | High affinity small molecule C5a receptor modulators | NEUROGEN CORPORATION | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027158-A1 | High affinity small molecule C5a receptor modulators | C3AR1, C5AR1, C5AR2 | C5AR1 2/4885CXCR3 83/4885CNR2 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.